CMPX Earnings Date: Nov 4, 2026 (Estimated) — Compass Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is CMPX's next earnings date?
Compass Therapeutics, Inc. (CMPX) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.12 on revenue of $229,250.
How did CMPX do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Compass Therapeutics, Inc. posted EPS of -$0.13 versus the -$0.11 estimate, a miss of 18.2%. Revenue was $0 against a $-600,000 estimate. The stock's 1-day post-earnings move was +5.3%.
How much does CMPX stock move after earnings?
CMPX beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.1% (up or down) in the day after earnings.
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.11 | -0.13 | -18.18% | $0 | ❌ Miss | +5.29% | +25.40% | +25.40% |
| 2026-05-05 | Q1 2026 | -0.10 | -0.10 | +0.00% | $0 | ➖ Inline | +0.52% | -5.67% | +8.25% |
| 2026-03-05 | Q4 2025 | -0.09 | -0.09 | +0.00% | $0 | ➖ Inline | -2.81% | -1.76% | -4.22% |
| 2025-11-05 | Q3 2025 | -0.14 | -0.08 | +42.86% | $0 | ✅ Beat | +0.79% | +22.16% | +46.17% |
| 2025-08-11 | Q2 2025 | -0.12 | -0.14 | -16.67% | $0 | ❌ Miss | +23.70% | +10.00% | +28.89% |
| 2025-02-27 | Q4 2024 | -0.09 | -0.11 | -22.22% | $0 | ❌ Miss | -1.68% | -6.73% | -29.29% |
| 2024-08-12 | Q2 2024 | -0.10 | -0.10 | +0.00% | $850,000 | ➖ Inline | +3.67% | +6.42% | +44.95% |
| 2024-05-13 | Q1 2024 | -0.11 | -0.08 | +27.27% | $0 | ✅ Beat | -2.50% | +0.00% | -23.75% |
Showing last 8 quarters.